RAC

2.20%

$1.78 race oncology ltd

Pillar 1 - FTO (new thread), page-300

First 300 Last

Share
Profile

Follow
Jdmoney

2,042 Posts.

353

04/03/21

14:02

Post #: 51517702
Share

Originally posted by Titans19: ↑

ha... the only negative opinions I have are on how the finances are done. I hope now given where the share price is most understand my frustrations over the past 12 months.

I've always been very bullish on what we know for Bisantrene and the science.

If I had any 'negative' opinion on the science it would be:

Pillar 1 - just because it worked in mice it doesn't mean it'll work in humans. (I am very optimistic though).. We also need to consider correlation or causation. Although, I like the potential hypothesis for Pillar 1 and I again am very optimistic.

Pillar 2 - Previous trials were a fail due to poor trial design so I don't give too much credit to them. Plus new treatments have set a very high bar, and liposomal treatment helps with cardio toxicity therefore the cardio benefit isn't as great if efficacy isn't there (IMO - I would always roll the die on cardio if survival was higher). However, after looking at the MST report and their suggested trial, plus some personal experiences we are going through with a friend resulting in me doing more scientific research (as best I can), I am again very optimistic on this Pillar as well.

Pillar 3 - well there's no negative to this Pillar. It's locked in in my opinion. I just hope they do a good trial design, get the PRV and get this approved as soon as possible. I would like to see Bisantrene approved and treating people for AML and also used off label.

That's about as good as I can get for 'negative' opinions on the science... I have a massive negative list on the financials! ha..

Plus I don't like to count my chickens before they hatch. Especially with the overall risks involved in Pillar 1 and 2 (trial design, efficacy, competition, time, etc).

IMO, DYOR, etc

Expand

I appreciate that you air your "negative" concerns!

it lets me keep things in check. I think as much as we hear positive, I continue to appreciate your measured views.

id be happy to hear your negatives on financials, if you are willing.

RAC Price at posting: $3.79 Sentiment: Hold Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

NAM

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The market's shrugged at China's stimulus measures all year. Why is this one different?

There are more pages in this discussion • 2,710 more messages in this thread...

First 300 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.78		Change -0.040(2.20%)		Mkt cap ! $302.5M

Open	High	Low	Value	Volume
$1.81	$1.82	$1.76	$132.8K	74.40K

Buyers (Bids)

No.	Vol.	Price($)
1	170	$1.77

Sellers (Offers)

Price($)	Vol.	No.
$1.78	2	1

View Market Depth

No.	Vol.	Price($)
1	170	1.765
2	4000	1.755
3	12714	1.750
1	3000	1.740
1	1405	1.720

Price($)	Vol.	No.
1.775	2	1
1.780	3781	1
1.820	2315	1
1.830	7500	1
1.840	1000	1

Last trade - 16.10pm 27/09/2024 (20 minute delay)

RAC (ASX) Chart

Pillar 1 - FTO (new thread), page-300

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Zeta Resources seeks to resolve the Panoramic takeover story

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The market's shrugged at China's stimulus measures all year. Why is this one different?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Pillar 1 - FTO (new thread), page-300

Top Stories

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Zeta Resources seeks to resolve the Panoramic takeover story

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The market's shrugged at China's stimulus measures all year. Why is this one different?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News